Innoxa has sold its eye care activity to Biosynex Group
The private shareholders of Laboratoires Innoxa have sold the company’s eye care activity to Biosynex Group.
Founded in 1920 in Paris by Dr. François Debat, a French pharmacist, Laboratoires Innoxa is a premium brand recognized worldwide for its expertise in the field of ophthalmology and optics. In 2020, the company was acquired by Frédéric and Laetitia Poux, who conducted a complete refoundation of the portfolio. The brand launched its first products in September 2021 and a new patented best-seller – the blue eye drops – in June 2022. Innoxa’s eye care activity now includes seven references with patented formulas, which comply with the latest European health and safety standards. The company’s product portfolio is structured around four areas: eye drops, eye sprays, contactology and optical sprays. The brand distributes its products in several countries, mostly in Europe and Asia, with core markets in France and China. Innoxa has a multichannel strategy with a historical presence in pharmacies and a focus on online platforms such as Amazon.fr and e-parapharmacies.
Founded in 2005, Biosynex is a leading public health player in France and Europe. The group offers innovative healthcare solutions to a wide range of users through two divisions: Biosynex Pharma (specialized in self-diagnostics and family health products) and Biosybex Diagnostic (developing and offering in vitro diagnostic medical devices). The group employs over 500 people, has a presence in 95 countries, and generated approximately US$212 in sales in 2022.
Oaklins’ team in France acted as M&A advisor to Laboratoires Innoxa in this transaction.
联系交易团队
相关交易
UniKidz has partnered with Karmijn Kapitaal
Karmijn Kapitaal has acquired a majority stake in UniKidz, a talent development organization that provides a scientifically-based developmental approach through high-quality childcare. Through the partnership with Karmijn Kapitaal, UniKidz can take the next step in bringing their unique concept to even more children.
更多信息Provital GmbH has been acquired by EMERAM Capital Partners
Dr. Thomas Brandner has sold a majority stake in Provital GmbH to private equity firm EMERAM Capital Partners. The transaction secures the future development and growth opportunities of the pet food company as EMERAM Capital Partners takes on ownership and acts as its strategic partner.
更多信息Venus Wine & Spirit Merchants plc has been acquired by Booker Group Ltd., a subsidiary of Tesco plc
The shareholders of Venus Wine & Spirit Merchants plc have sold the company to Booker Group Ltd., a subsidiary of Tesco plc. The move allows the Tesco subsidiary to bolster its on-trade portfolio through the addition of Venus’ range of over 2,000 spirits, beers, wines and soft drinks.
更多信息